{"id":"NCT03830866","sponsor":"AstraZeneca","briefTitle":"Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)","officialTitle":"A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-02-15","primaryCompletion":"2022-01-20","completion":"2023-07-03","firstPosted":"2019-02-05","resultsPosted":"2023-03-06","lastUpdate":"2024-07-26"},"enrollment":770,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Locally Advanced Cervical Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Durvalumab","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"RADIATION","name":"external beam radiation therapy (EBRT) + brachytherapy","otherNames":[]}],"arms":[{"label":"Durvalumab (intravenous infusion)","type":"EXPERIMENTAL"},{"label":"Placebo (matching placebo for intravenous infusion)","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer","primaryOutcome":{"measure":"Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression","timeFrame":"Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months","effectByArm":[{"arm":"Durvalumab + SoC CCRT","deltaMin":null,"sd":null},{"arm":"Placebo + SoC CCRT","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.174"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":117,"countries":["United States","Brazil","Chile","China","Hungary","India","Japan","Mexico","Peru","Philippines","Poland","Russia","South Africa","South Korea","Taiwan"]},"refs":{"pmids":["38039991","32447296"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&parentIdentifier=D9100C00001&attachmentIdentifier=a290db6a-1ec0-4b2d-a142-1d9d56d6fffc&fileName=D9100C00001-CSR_synopsis_Revised_Redacted_PDFA.pdf&versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D9100C00001&amp;attachmentIdentifier=aa6dc71f-9108-4682-ba4e-39a3ef218fde&amp;fileName=d9100c00001-CSR_addendum.pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":113,"n":385},"commonTop":["Nausea","Anaemia","Diarrhoea","Vomiting","Constipation"]}}